Inotiv, Inc. (NOTV) Stock Score, Valuation & Financial Research
Inotiv, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for NOTV
Inotiv, Inc. currently has a Wall Street Score of 17/100. The stored market price is $0.08. Its financial score is 7/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Inotiv, Inc. does
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
NOTV financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $0.08
- Market capitalization:
- $2.8M
- Revenue:
- $507.4M
- Net income:
- $-87.0M
- Free cash flow:
- $-27.1M
- Cash:
- $15.2M
- Total debt:
- $487.8M
- EPS:
- -2.11
- Financial score:
- 7/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-27.1M, showing cash burn in the current stored period.
- The balance sheet shows $15.2M of cash versus $487.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 7/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NOTV
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.